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X-box binding protein 1 (XBP1) is a central regulator of the endoplasmic reticulum (ER) stress response.
It is induced via activation of the IRE1 stress sensor as part of the unfolded protein response (UPR) and
has been implicated in several diseases processes. XBP1 can also be activated in direct response to Toll-
like receptor (TLR) ligation independently of the UPR but the pathogenic signiﬁcance of this mode of
XBP1 activation is not well understood. Here we show that TLR-dependent XBP1 activation is operative
in the synovial ﬁbroblasts (SF) of patients with active rheumatoid arthritis (RA). We investigated the
expression of ER stress response genes in patients with active RA and also in patients in remission. The
active (spliced) form of (s)XBP1 was signiﬁcantly overexpressed in the active RA group compared to
healthy controls and patients in remission. Paradoxically, expression of nine other ER stress response
genes was reduced in active RA compared to patients in remission, suggestive of a UPR-independent
process. However, sXBP1 was induced in SF by TLR4 and TLR2 stimulation, resulting in sXBP1-
dependent interleukin-6 and tumour necrosis factor (TNF) production.
We also show that TNF itself induces sXBP1 in SF, thus generating a potential feedback loop for sus-
tained SF activation. These data conﬁrm the ﬁrst link between TLR-dependent XBP1 activation and hu-
man inﬂammatory disease. sXBP1 appears to play a central role in this process by providing a
convergence point for two different stimuli to maintain activation of SF.
 2013 The Authors. Published by Elsevier Ltd. All rights reserved.1. Introduction
The pathogenesis of rheumatoid arthritis (RA) is complex, and
although not fully elucidated, it is widely accepted that joint
inﬂammation anddamage result fromthe interplayandactivationof
the resident synovial ﬁbroblasts (SF) by self-reactive immune cells
[1]. Activated SF demonstrate an enhanced survival and destructive
phenotype, thought to result in part from dysregulation of the
unfolded protein response (UPR), with accompanying ER associated
degradation (ERAD) [2e4]. The activation of X-box binding protein 1
(XBP1) by inositol-requiring 1a(IRE1) is the most evolutionarilyBY-NC-SA license (http://
x: þ44 113 343 8502.
McDermott).
Published by Elsevier Ltd. All righconserved component of the UPR. XBP1 is a transcription factor (TF)
that regulates numerous genes involved in adaptation to ER stress.
XBP1 activation depends on the IRE1-dependent removal of 23
nucleotides from the XBP1 mRNA with the resultant frameshift
encoding a more stable TF with enhanced transactivation potential.
More recently, XBP1 splicing has beendemonstrated downstreamof
Toll-like receptor (TLR) 2 and TLR 4 ligation [5]. This process requires
phosphorylation of IRE1, which cleaves XBP1 mRNA thereby
generating the spliced, active form (s)XBP1; this occurs in the
absence of ER stress orwiderUPRactivation and leads to synthesis of
the pro-inﬂammatory cytokines, TNF and IL-6 [5]. Recently, it has
been demonstrated that myeloid speciﬁc deletion of IRE1 protects
mice from inﬂammatory arthritis [6]. Furthermore, the same effect
was observed in mice treated with an IRE1-speciﬁc inhibitor. In this
system IRE1 was required for optimal production of inﬂammatory
cytokines resulting from TLR stimulation.ts reserved.
S. Savic et al. / Journal of Autoimmunity 50 (2014) 59e6660This pathway linking TLR2- and TLR4-dependent XBP1 activa-
tion to TNF and IL-6 secretion may have particular relevance to RA,
since both TLR2 and TLR4 are highly expressed in the RA joints [7]
and biologic therapies that target TNF and IL-6 are effective in a
large number of patients. Although TLRs are primarily involved in
pathogen sensing, they also recognise several endogenous ligands
and it is these that may be particularly relevant in the setting of RA
[8e11]. The endogenous TLR2 ligand, SNARE associated protein
(SNAPIN), was recently identiﬁed as being highly expressed in sy-
novial tissue macrophages and consequently SNAPIN has been
suggested to contribute to the pathogenesis of RA [12].
We set out to investigate the relevance of interactions between
UPR and TLR signalling pathways in the serum and SF of patients
with RA, using osteoarthritis (OA) samples as controls. Our results
reveal that, in both serum and SF of RA patients, generation of
sXBP1 is uncoupled from the canonical UPR-response, while TLR2
and TLR4 stimulation by endogenous ligands, such as SNAPIN,
facilitate the production of pro-inﬂammatory cytokines.2. Materials and methods
2.1. Patients and cells
The active RA group included patients with established disease
who had failed at least 2 traditional disease-modifying anti-rheu-
matic drugs (DMARDs), and were about to commence either
inﬂiximab or adalimumab. The RA remission group included pa-
tients who were treated with anti-TNF agents, inﬂiximab or adali-
mumab, and who later achieved complete clinical (DAS <1.2),
biochemical (CRP <10) and radiological remission (no evidence of
synovitis on ultrasound scan), and who were subsequently main-
tained off all therapy. Ethical committee approval was granted by
the UK Central Ofﬁce of Research Ethics Committee (RA cohort: 01/
023, HC: 04/Q1206/107).
PBMC were obtained from patients and control groups by den-
sity gradient centrifugation (Lymphoprep-Sigma, Aberdeen, UK). SF
were obtained by collagenase (StemCell Technologies, Grenoble,
France) digestion of synovial biopsies from RA and OA patients who
had undergone consented arthroscopy of a swollen knee joint. SF
were selected as the adherent cells following culture in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) containing foetal bovine serum
(FBS) (10% v/v) and penicillin-streptomycin (1% v/v). After reaching
conﬂuence, the cells were passaged and replated at a ratio of 1:3.
The cells were used at passage 3 (P3).2.2. qRT-PCR and sXBP1 detection
Total RNA was isolated using TRIzol (Invitrogen, Paisley, UK)
from PBMC and cultured SF and ﬁrst-strand cDNA synthesized us-
ing Superscript II Reverse transcriptase (Invitrogen).
XBP1 mRNA splicing was detected using the following set of
primers: Fe50-CTGAAGAGGAGGCGGAAGC-30 andRe50-AATACCGCC
AGAATCCATGG-30, which recognise both the shorter spliced (s) and
longer unspliced (u) forms of XBP1mRNA. sXBP1was then identiﬁed
on a 3% agarose gel as the faster migrating species of the two closely
spaced bands.
Primers for quantitative real-time PCR (qPCR); unspliced XBP1
(uXBP1) forward 50-TCCGCAGCACTCAGACTACG-30, sXBP1 forward
50-CTGAGTCCGCAGCAGGTG-30 and reverse primer for u/sXBP1 50-A
GTTGTCCAGAATGCCCAACA-30, ﬁnal concentration 50 fmol/ml. For-
ward uXBP1 primer spans the splice site to avoid amplifying sXBP1
and primer pairs span different exons. Relative gene expression
(2(eDCT)) was analysed using SDS 2.3 (Applied Biosystems), nor-
malising to hypoxanthine phospho- ribosyltransferase 1 (HPRT):Forward50-GGAAAGAATGTCTTGATTGTGGAAG-30 andreverse50-G
GATTATACTGCCTGACCAAGGAA-30, ﬁnal concentration 500 fmol/ml.
All reactionswere carried out in duplicate using SYBRgreenon theABI
7900 (Applied Biosystems), using standard cycling parameters. Stan-
dard SYBR green PCR conditions were used, with an annealing tem-
perature of 59 C and40 cycles. Optimisation stepswere carried out to
ensure speciﬁcity of primer pairs to amplify individual u/sXBP1 cDNA
products.
A custom TaqMan gene array based on a 384-well micro ﬂuidic
card was designed using the Applied Biosystems website (www.
appliedbiosystems.com), to determine the expression of a num-
ber of UPR genes of interest. These included: Synoviolin (SYVN1),
thioredoxin domain-containing protein 4 (TXNDC4), Inositol-requiring
protein 1 (IRE1), homocysteine-responsive endoplasmic reticulum-
resident ubiquitin-like domain family member 2 (HERPUD2), Heat
shock 70 kDa protein 5 (HSPA5), Growth arrest and DNA damage-
inducible protein (GADD34), C/EBP-homologous protein (CHOP), Pro-
tein disulﬁde isomerase family A, member 4 (PDIA4)DnaJ (Hsp40)
homolog, subfamily B, member 9 (DNAJB9). The analysis was done
using DataAssist software from Applied Biosystems (Foster City,
CA, USA). The relative gene expression was calculated with refer-
ence to the housekeeping gene, GAPDH. Difference between the
cycle thresholds for GAPDH and the selected genes (DCt) was
determined and relative gene expression calculated as 2DCt Results
were plotted as relative expression units (REU).
UPR genes expression from synovium 100 micron sections of OCT
embedded synovial tissue were cut and the OCT manually removed.
RNA was extracted using Norgen ANimal Tissue RNA kit. Reverse
transcriptionwasperformedusingHighcapacity reverse transcription
(AppliedBiosystems). Taqmanassayswereperformedusing following
primer sets: Hs99999905_m1 GAPDH, Hs00381211_m1 SYVN1,
Hs00231936_m1 XBP1, Hs99999174_m1 HSPA5, Hs01052402_m1
DNAJB9.
2.3. Flow cytometry
Intracellular staining for sXBP1 was performed ﬁxation/per-
meabilization buffer (Bioscience, Hatﬁeld, UK). The primary anti-
body was mouse monoclonal anti-human sXBP1 [gift from Dr. G.
Doody and Dr. R. Tooze [13]]. Mouse polyclonal IgG2 (AbD Serotec,
Oxford, UK) was used as an isotype control, while polyclonal goat
anti-mouse FITC (ﬂuorescein isothiocyanate) conjugate and FITC
labelled polyclonal (Southern Biotech, Birmingham, AL, USA) was
used as the secondary antibody. Samples were analysed using a 1-
colour protocol on the BD LSRII ﬂow cytometer (BD Biosciences,
Cowley, UK). Median of ﬂuorescence intensity (MFI) was used to
measure the expression levels of the intracellular protein.
2.4. Immunoﬂuorescence
SF for IFwere grownoncoverslips.Adherent cellswereﬁxedusing
ice-cold 100%methanol for 5 min at20 C. Appropriate dilutions of
the primary anti-human sXBP1 antibody (as above) were added. The
primary antibodies were visualized using Alexa Fluor 680 goat anti-
mouse secondary Ab or FITC. DAPI (1:1000) was used to visualise
nuclei (blue). Images were analysed using Andor IQ software.
2.5. Cell stimulation
RA and OA SF were treated with 10 ng/ml of LPS (Sigma) for 6 h,
with or without prior incubation with the speciﬁc TLR4 inhibitor
CLI-095 (Invivogen) or a TLR2/4 inhibitor, OxPAP (Invivogen), for
30 min. Stimulation of SF with 5 mg/ml of SNAPIN (Reagent Pro-
teins) for 24 h. Treatment with Tg (Sigma) was used as a control for
induction of ER stress by treating the SF with 300 nM for 6 h.
Fig. 1. sXBP1 expression in PBMC. (A) XBP1 splicing was determined by PCR, using primers that amplify both unspliced and spliced mRNA species. RA-ACT1 and 2 (RA patients with
active disease); OA1- and OA2-osteoarthritis patients; RA-REM1 and 2 (RA patients in remission); HC, healthy control. (B) sXBP1 mRNA levels were determined by qRT-PCR and
expressed as relative to levels of GAPDH. Data are shown as median with interquartile range. Statistical analysis of variance between different of groups was performed using the
KruskaleWallis test and Dunn’s Multiple Comparison Test was used to compare all pairs of data. (* ¼ p < 0.05). (C) sXBP1 protein expression in PBMC was analysed by ﬂow
cytometry. Expression levels are shown as median ﬂuorescence intensity (MFI) on the y-axis. Statistical signiﬁcance was determined using non-parametric ManneWhitney U test.
Table 2
List of UPR genes alternative names and function.
UPR gene Full and alternative names Transcription
control
Function
SYVN1 Synovial apoptosis inhibitor 1 sXBP1,
?ATF6
ERAD, E3ligase
TXNDC4 ERP44 (ER protein 44) sXBP1 Chaperone
Disulﬁde bond
formation
Cell redox
homeostasis
PDIA4
(ERP70/72)
Protein disulﬁde isomerase
family A, member 4
sXBP1 Cell redox
homeostasis
DNAJB9 DnaJ (Hsp40) homolog,
subfamily B, member 9
sXBP1 Heat shock
protein
Protein folding
HERPUD2 Homocysteine-responsive
endoplasmic reticulum-
resident
ubiquitin-like domain family
member 2
ATF4
ATF6
Co-chaperone
BIP (HSPA5) Immunoglobulin heavy
chain-binding protein
(Heat shock 70 kDa protein 5)
ATF4
ATF6
Chaperone
GADD34
(PPP1R15A)
Growth arrest and DNA
damage-inducible protein
ATF4
ATF6
Apoptosis
Cell cycle arrest
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Cytokine levels were quantiﬁed from media supernatants using
ELISA kits for IL-6 (BD Biosciences) and TNF (PeproTech), according
to the manufacturers’ instructions.
2.7. siRNA knock down
Human XBP1 was targeted for knock down by RNA interference
using siRNA (ON-TARGET plus SMART pool, Thermo Scientiﬁc) in
RA SF for 48 h. Non-targeting control (ON-TARGET plus Non-
targeting siRNA, Thermo Scientiﬁc) was also used according to
manufacturers’ instructions.
2.8. Statistical analyses
The KruskaleWallis and Dunn’s Multiple Comparison Test (pot-
hoc analysis) were used for one-way analysis of variance between
multiple groups of patients. The ManneWhitney test was used to
analyse differences between sXBP1 protein expression in RA-ACT
and HC PBMC. Spearman’s rank correlation coefﬁcient was used
to determine the degree of association between sXBP1 mRNA
expression and joint inﬂammation.
3. Results
3.1. sXBP1 is upregulated in PBMC from patients with active RA
We reasoned that if XBP1 activation is involved in RA patho-
genesis then the activation of XBP1, detectable by splicing of its
mRNA, should be associated with disease activity. We thereforeTable 1
Demographics of patients with RA and HC used in UPR gene expression studies.
Groups HC RA-ACT RA-REM
Number 24 47 12
Av Age (Range) 45.4 (24e68) 56.9 (23e83) 57.0 (47e64)
F:M (%) 15F:9M (62.5e37.5) 40F:7M (85:15) 10F:2M (83:17)
% ACPA pos 0 83 80
ACPA- anti citrullinated protein antibody.compared the expression of XBP1 and sXBP1 mRNA, using reverse
transcription (RT)-PCR, in patients at different stages of disease. We
used mRNA from peripheral blood mononuclear cells (PBMC) ob-
tained from RA patients with active disease (RA-ACT), or remission
(RA-REM), and compared to either healthy individuals (HC) or
those with OA as controls. The sXBP1 species was detected in PBMC
of patients with active RA, but not those in remission, and neither
was it detected in OA patients or healthy controls (Fig. 1A). We then(Protein phosphatase 1,
regulatory (inhibitor)
subunit 15A)
Regulation of
translation
Response to
DNA damage
CHOP (DDIT3) C/EBP-homologous protein
(DNA-damage-inducible
transcript 3)
ATF4
ATF6
Transcription
regulation
Growth arrest
Apoptosis
IRE1 (ERN1) Inositol-requiring protein 1
(Endoplasmic reticulum to
nucleus signalling 1)
? sXBP1 activation
Apoptosis
UPR
S. Savic et al. / Journal of Autoimmunity 50 (2014) 59e6662used quantitative (q)RT-PCR to conﬁrm these results in a wider
group of patients [active RA (n ¼ 47), and remission (n ¼ 12)]
(demographics Table 1) as well as HC (n ¼ 24). This conﬁrmed that
the highest expression levels of sXBP1were observed in PBMC of RA
patients with active disease (Fig. 1B).
We also conﬁrmed sXBP1 protein expression in PBMC using
ﬂow cytometry; 10 RA-ACT patients had signiﬁcantly higher mean
sXBP1 expression levels compared to 7 sex- and age-matched HC
(p ¼ 0.01, Fig. 1C). Collectively, these results reveal a signiﬁcant
association between sXBP1 expression and the active RA pheno-
type (Fig. 1).
3.2. UPR responsive genes are downregulated in PBMC of RA
patients
The association of sXBP1 expression with RA pathogenesis
suggested a potential role for the UPR in this disease. The UPR is
characterized by three primary arms leading to activation of XBP1
and the activating transcription factors (ATF) 4 and ATF6. Several
target genes have been deﬁned for these TFs, providing a signature
of the canonical UPR. In order to assess whether the observed XBP1Fig. 2. Expression of UPR genes in PBMC of RA patients and healthy controls. Levels of UPR
GAPDH. Samples were healthy controls (HC; n ¼ 24), RA with active disease (RA-ACT; n ¼
logarithmic scale (Log 10). Statistical analysis of variance between different of groups was
used to compare all pairs of data. Data are shown as median with interquartile range. (* ¼activation in active RA was associated with a canonical UPR we
measured expression of 9 genes from this UPR signature (Table 2).
Surprisingly, the expression of eight of nine signature genes was
downregulated in RA patients with active disease when compared
to the RA remission group and the HC group (Fig. 2). For example,
the expression levels of SYNV1, TXNDC4, HERPUD2, IRE-1, HSPA5 and
PDIA4were all signiﬁcantly reduced in active RA patients compared
to HC (all p < 0.05). In the case of HERPUD2, HSPA5 and PDIA4, their
expression in the RA group with active disease was also signiﬁ-
cantly lower compared to the group of patients in remission
(p < 0.05, p < 0.01 and p < 0.001 respectively). The RA-remission
group also had signiﬁcantly higher expression of GADD34, and
CHOP compared to patients with active RA (p < 0.001 and
p< 0.005) and, in the case of CHOP and PDIA4, the expression levels
in remission patients were signiﬁcantly higher in comparison to HC
(p< 0.01 and p< 0.005). Only in the case of DNAJB9was expression
unaffected by disease activity. Overall, patients with active RA had
the lowest expression levels of UPR target genes compared to other
groups, despite increased expression of the sXBP1 species in this
group. These results suggested that XBP1 pathway was uncoupled
from other elements of a canonical UPR.genes (as indicated) were determined by qRT-PCR and expressed relative to levels of
47) and RA in remission (RA-REM; n ¼ 12). Values on the Y-axis are presented on a
performed using the KruskaleWallis test whilst Dunn’s Multiple Comparison Test was
p < 0.05, ** ¼ p < 0.01, *** ¼ p < 0.005 and **** ¼ p < 0.001).
S. Savic et al. / Journal of Autoimmunity 50 (2014) 59e66 633.3. TLR2 and TLR4 mediated sXBP1 activation in synovial
ﬁbroblasts (SF)
The association of sXBP1 with RA pathogenesis was further
supported by the ﬁnding that there was a trend for higher
expression of sXBP1 in RA (p ¼ 0.131) compared to OA synovial
biopsies (20 RA and 12 OA) (Fig. 3A). There was also a direct rela-
tionship with levels of inﬂammation in the joint (RA and OA
combined), as measured using arthroscopic inspection (Spearman
r¼ 0.678, p¼ 0.068) (Fig. 3B). Expression of the HSPA5, DNAJB9 and
SYVN1was not different between patients with RA and OA and was
unrelated to the degree of inﬂammation (Fig. 3C).
However, sXBP1 mRNA was not detectable in cultured SF ob-
tained from either the active RA or OA synovial biopsies (Fig. 3D).
The lack of detectable sXBP1 in these cultured RA synovial ﬁbro-
blasts suggested the removal of an in vivo stimulus. Martinon et al.
have previously shown that XBP1 splicing can occur in response to
TLR2 or TLR4 ligation, via IRE1 phosphorylation, and that this oc-
curs in the absence of a more generalized UPR [5]. We hypothesised
that a similar mechanism might be responsible for the UPR-
independent sXBP1 induction observed in RA patients. Stimula-
tion of SF with LPS (the prototype TLR4 ligand) induced sXBP1
expression, and this effect was antagonized by a TLR4 pathway
inhibitor, CLI-095 (Fig. 4A). However, as the inﬂammatory response
in RA is sterile, we tested the role of the endogenous TLR ligand,
SNAPIN, in sXBP1 induction. SNAPIN, a component of SNARE com-
plexes, is a TLR2/4 ligand that has been implicated in the patho-
genesis of RA [12]; SNAPIN induced sXBP1 to similar levels as that
seen with LPS, and this effect was abrogated by using a selectiveFig. 3. Expression of sXBP1 and UPR genes in synovium. (A) sXBP1mRNA levels in RA and OA
(B) Correlation between sXBP1 mRNA levels and synovial inﬂammation, which was determin
signiﬁcance determined using Spearman rank correlation coefﬁcient (C) SYNV1, HSPA5 and
determined by ManneWhitney test. (D) XBP1 splicing determined by RT-PCR, using prime
treated with DTT (to induce a UPR). RA SF were obtained from a rheumatoid joint (knee) aTLR4 inhibitor or as a result of combined TLR4/2 inhibition by
OxPAPC (Fig. 4A).
3.4. SNAPIN-induced cytokine production is dependent on sXBP1
Martinon et al. have demonstrated that TLR activation of XBP1 is
required for the production of inﬂammatorymediators, such as IL-6
and TNF, by macrophages. Both LPS and SNAPIN induced IL-6 and
TNF secretion by RA SF (Fig. 4B and C). This correlation of cytokine
secretion and sXBP1 expression lead us to investigate if SNAPIN-
induced cytokine production in SF is dependent on sXBP1 expres-
sion. We used siRNA to selectively inhibit expression of sXBP1 prior
to stimulation with SNAPIN (Fig. 5A). Furthermore, SNAPIN-
induced IL-6 production was inhibited in the absence of sXBP1
(Fig. 5B). That this was a non-canonical response was further
revealed by the fact that thapsigargin (Tg), a potent activator of the
UPR, failed to induce IL-6 despite generating signiﬁcant amounts of
sXBP1 (Fig. 4B). However, this situation was different in the case of
TNF, which was produced by RA SF following stimulation with Tg
(Fig. 4C).
3.5. Activation of RA SF is sustained by an autocrine loop
downstream of XBP1 activation by pro-inﬂammatory cytokines
Pro-inﬂammatory conditions may themselves contribute to
XBP1 activation. To replicate the pro-inﬂammatory conditions of
the RA joint and to determine their effect on XBP1 mRNA splicing,
we incubated RA synoviocytes with a combination of different pro-
inﬂammatory cytokines known to have a role in the pathogenesis of-SF determined by qRT-PCR. Statistical signiﬁcance determined by ManneWhitney test.
ed using visual analogue scale following arthroscopic inspection of the joint. Statistical
DNAJB9 mRNA levels in RA and OA-SF determined by qRT-PCR. Statistical signiﬁcance
rs that amplify both unspliced and spliced mRNA species. Neg, cells at rest; Pos, cells
nd cultured to P3, OA SF obtained from an OA patient (knee joint) and cultured to P3.
Fig. 4. sXBP1, IL-6 and TNF expression in SF following stimulationwith LPS and SNAPIN. 4. (AeC) sXBP1 mRNA levels in RA SF measured by qRT-PCR after treatment with LPS (10 ng/
ml) for 6 h, TLR4 inhibitor (1 mg/ml) for 30 min followed by LPS (10 ng/ml) for 6 h, SNAPIN (5 mg/ml) for 24 h, with or without prior TLR4 (1 mg/ml) and TLR2/4 (30 mg/ml) inhibition
for 30 min, and Tg (300 nm/ml) for 6 h with or without TLR2/4 (30 mg/ml) treatment, with DMSO as vehicle control. Results are expressed relative to HPRT. Error bars represent the
standard deviation of 3 independent experiments. (BeC) Supernatants were harvested from RA SF and IL-6 and TNF levels were determined by ELISA, the X-axis represents the
different treatments described above. Error bars represent the standard deviation of 3 independent experiments.
S. Savic et al. / Journal of Autoimmunity 50 (2014) 59e6664RA. sXBP1mRNAwas generated following incubation of the SF with
10 ng/ml TNF for 24 h, but not after similar stimulationwith IL-6 or
IL-1b. However, the combination of TNF, IL-6 and IL-1b induced
stronger activation of sXBP1 then TNF alone (Fig. 6A). Furthermore,
immunoﬂuorescence microscopy of TNF stimulated SF demon-
strated the localisation of sXBP1 to the nucleus, similar to the
localisation observed after Tg treatment (Fig. 6C). Thus RA SF can
respond to TNF secretion by inducing sXBP1, and sXBP1, in turn, is
linked to inducible cytokine secretion.
4. Discussion
In this study we have demonstrated that XBP1 activation is
implicated in RA pathogenesis and that this is uncoupled from a
canonical UPR signature in this disease. Furthermore, XBP1 splicing
is induced in response to TLR activation and is involved in TLR-
dependent cytokine secretion. Finally, the same cytokines
induced in response to TLR2 and TLR4 activation, can themselves
induce splicing of XBP1 in synoviocytes. As a result of these in-
teractions there is a potential autocrine loop, linking speciﬁc TLRs
to sXBP1 formation, cytokine secretion and sustained synthesis of
sXBP1 mRNA. During preparation of this manuscript Qui et al.
published ﬁndings, which also show a critical role for IRE1 in the
pathogenesis of a murine serum transfer model of RA [6]. Similar to
our ﬁndings they also demonstrated overexpression of sXBP1 in RA
patients compared to OA, but the majority of their results, which
showed a critical role for TLR-dependent IRE1 activation in the
production of variety of inﬂammatory mediators, were based on an
animal model. Our study not only further supports thisproinﬂammatory role for IRE1-sXBP1 signalling axis, but it also
demonstrates the direct relevance of this biological process in pa-
tients with RA, and that this pathway can be altered by therapies
such as anti-TNF biologics.
Dysregulation of the UPR has previously been implicated in the
pathogenesis of RA. This notionwas ﬁrst proposed after SYNV1 was
found to be highly expressed in RA synovium and was associated
with increased survival of RA SF [2]. More recently, glucose-
regulated protein-78 (GRP78), (also known as Bip and HSPA5),
has been identiﬁed as a marker of ER stress and UPR dysregulation
in RA [14]. The expression of GRP78 was induced by TNF and its
expression was associated with SF proliferation and angiogenesis,
two key pathological features of RA. However, GRP78 has also been
implicated in resolution of inﬂammation and has been proposed to
have an immunoregulatory role [15]. For this reason it has been
included in a group of endogenous proteins collectively named the
resolution-associated molecular pattern (RAMP) family of mole-
cules. Clinical trials delivering GRP78 to RA patients are currently in
progress and preliminary data from phase I and II studies have
shown some efﬁcacy [15].
The full extent of UPR involvement in RA pathogenesis remains
to be established. Indeed it is likely that proteins such as XBP1
might have more then one role in this process. Traditionally initi-
ation of the UPR was thought to involve activation of three path-
ways: protein kinase-like endoplasmic reticulum kinase (PERK),
ATF6 and IRE1a, which leads to splicing of XBP1. However under
certain circumstances, IRE1 activation and generation of sXBP1 can
also occur independently of the other two pathways. For example,
LPS-mediated engagement of TLR4leads to inhibition of CHOP
Fig. 5. sXBP1 knock down and IL-6 expression following stimulation with SNAPIN. (A)
qRT-PCR determining sXBP1 levels in RA SF after siRNA transfection, targeting either
XBP1 (siXBP1) or a non-targeting control (siNT) for 48 h in total. Cells were treated
with SNAPIN (5 mg/ml) for 24 h. (B) IL-6 levels in culture supernatants measured by
ELISA after XBP1 knock down and SNAPIN treatment.
Fig. 6. sXBP1 expression in response to pro-inﬂammatory cytokines (A) sXBP1 mRNA
levels in RA-SF determined by qRT-PCR following treatment with LPS (10 ng/ml) for
6 h, TNF, IL-1b, IL-6 (all used at concentration of 10 ng/ml) for 24 h (B) sXBP1
expression and subcellular localisation was determined by IF after SF were treated with
Tg (1 mM for 3 h) as a positive control and TNF (10 ng/ml for 48 h). Blue
(DAPI) ¼ nucleus; green (FITC) ¼ SYVN1; red (TRITC) ¼ sXBP1. Images taken at 640
magniﬁcation.
S. Savic et al. / Journal of Autoimmunity 50 (2014) 59e66 65expression and translational activation of ATF4 (regulated by PERK)
[16]. Subsequently it was shown that that XBP1 splicing can occur
in response to TLR2 or TLR4 ligation via IRE1 phosphorylation, and
this occurs in the absence of PERK or ATF6 activation [5]. More
recently we demonstrated involvement of (s)XBP1 and reactive
oxygen species (ROS) in the pathogenesis of tumour necrosis factor
receptor-associated periodic syndrome, a rare inherited auto-
inﬂammatory syndrome [17]. This condition is also characterized
by hyper-responsiveness to the LPS, suggesting a role for sXBP1/TLR
signalling axis.
This might explain why we detected a discrepancy between the
expression of sXBP1 and other UPR genes. The downregulation of
classical UPR associated genes in the context of sXBP1 expression,
shown here in PBMCs from active RA, supports the concept of se-
lective pathway and target gene activation under inﬂammatory
conditions. Considering the disease context this could reﬂect either
the effects of TNF or other pro-inﬂammatory cytokines, or, an as yet
to be identiﬁed danger associated molecular pattern (DAMP) mol-
ecule(s) released as a result of tissue damage that selectively en-
gage(s) the IRE1 pathway.
We decided to investigate this latter possibility, since TLR acti-
vation has been reported to play an important role in the patho-
genesis of RA. We have demonstrated TLR4 and TLR2 activation of
sXBP1 in RA SF that resulted in production of pro-inﬂammatory
cytokines, IL-6 and TNF, which are relevant to the pathogenesis of
RA. We then demonstrated that the TLR2/4 ligand, SNAPIN, can
induce IL-6 and TNF secretion by SF that is dependent on sXBP1
expression. Lastly we showed that TNF itself causes splicing of XBP1
in SF. The splicing of XBP1 in response to TNF stimulation was also
recently demonstrated by another group which investigated the
role of TNF in protein degradation pathways in RA SF [18]. Although
we have demonstrated a role for SNAPIN in TLR signalling in SF, it
remains unclear if this same ligand, under physiological conditions,
is likely to cause TLR activation and therefore XBP1 splicing in
PBMC. Themost probable targets herewould bemacrophages and apossible source of SNAPIN could be platelet-derived microparticles,
which have been demonstrated in both the synovial ﬂuid and
systemic circulation of patients with RA [19].
Although our study showed a discrepancy between expression
of sXBP1 and of other UPR genes, this does not necessarily
contradict the ﬁndings of previous studies published on this theme.
Abnormalities of UPR were still suggested in our experiments by
the fact that almost all the genes were downregulated in the active
RA group and their expression recovered in remission patients. This
pattern of UPR gene expression may result from metabolic adap-
tations occurring in cells following a period of chronic ER stress,
which ultimately might be damaging to the cell due to the associ-
ated global reduction in protein synthesis, and the risk of activating
the PERK axis and CHOP-mediated death pathways. To eliminate
this possibility, cells have evolved negative-feedback mechanisms
to control the magnitude of the UPR response. PERK, for example, is
negatively regulated by p58IPF, which is a transcriptional target of
both sXBP1 and ATF6 [20,21]. In addition, the negative effects of
PERK activation on global protein synthesis are reduced by
GADD34, which dephosphorylates eIF2a to re-initiate protein
synthesis [22].
5. Conclusions
sXBP1 plays a central role in two different cellular processes
which may ﬁrst appear unconnected. However the coupling of TLR
S. Savic et al. / Journal of Autoimmunity 50 (2014) 59e6666signalling with XBP1 activation may have evolved to protect the
inﬂammatory TLR-expressing cells, which, as a result of host
engagement against invading pathogens, may be exposed to pro-
longed levels of ER stress [23]. Physiologically, the linking of pro-
inﬂammatory pathways with activation of IRE1 provides these
cells with a timely, coordinated and protective response. XBP1
activation may therefore be a suitable target in the treatment of RA,
since it forms a cornerstone of two different molecular processes
implicated in the pathology of RA, namely hyper-ERAD and TLR-
mediated inﬂammatory response.
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